{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:39:26Z","timestamp":1791549566144,"version":"4.3.4"},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for the treatment of type 2 diabetes mellitus and obesity. Although gastrointestinal adverse effects are common, gastroparesis is an under-recognised but clinically important complication. This systematic review summarises published evidence on the presentation, diagnosis, management, and outcomes of gastroparesis associated with GLP-1RA therapy in real-world clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review was conducted in accordance with PRISMA 2020 guidelines. PubMed, Embase, Scopus, and Web of Science were searched from inception to October 2025 for reports of symptomatic gastroparesis associated with GLP-1RA use. Eligible studies included case reports, case series, observational studies, and clinical trials involving adults treated with GLP-1RAs for diabetes or weight loss. Data extraction focused on patient characteristics, GLP-1RA exposure, clinical presentation, diagnostic findings, management strategies, and outcomes. Methodological quality was assessed using the Joanna Briggs Institute checklist for case reports.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twelve case reports describing 13 patients met inclusion criteria. Most patients were female and had type 2 diabetes mellitus, though cases also occurred in non-diabetic individuals. Semaglutide was the most frequently implicated agent, followed by liraglutide, dulaglutide, and exenatide. Symptom onset ranged from hours to several months after treatment initiation, commonly following dose escalation or inappropriate re-initiation. Presentations varied from acute to chronic. Reported symptoms included nausea, vomiting, abdominal pain, bloating, early satiety, and oral intolerance. Diagnostic evaluation often demonstrated gastric distension or retained gastric contents on imaging or endoscopy in the absence of mechanical obstruction. Gastric emptying scintigraphy confirms delayed emptying in selected cases. Management primarily involved supportive and symptomatic care. Discontinuation of the offending GLP-1RA led to symptom resolution in all reported patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>GLP-1 receptor agonists may induce or worsen gastroparesis in both diabetic and non-diabetic patients, particularly following rapid dose escalation or inappropriate dosing. Awareness of this association is essential for timely diagnosis and management. Withdrawal of the causative agent is central to treatment and is associated with favourable outcomes and reversibility of gastric dysfunction. Careful patient selection, gradual dose titration, and monitoring for persistent gastrointestinal symptoms are recommended to optimise the safe use of GLP-1RAs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0354497","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T17:25:25Z","timestamp":1786641925000},"page":"e0354497","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Gastroparesis induced by glucagon-like peptide-1 receptor agonists: A systematic review of clinical features, diagnosis, management, and outcomes"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6274-5468","authenticated-orcid":true,"given":"Tope","family":"Olubodun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morenike Adedoyin","family":"Osundina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Olubukunmi","family":"Soyoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia Maria Bim","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayodeji Bamidele","family":"Olubodun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwatoyin Olanrewaju","family":"Ogundele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"issue":"1","key":"pone.0354497.ref001","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.462","article-title":"Glucagon-like peptide agonists: A prospective review","volume":"7","author":"Z Mariam","year":"2024","journal-title":"Endocrinol Diabetes Metab"},{"issue":"1","key":"pone.0354497.ref002","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12933-025-02647-2","article-title":"Correction: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and cardiometabolic protection: historical development and future challenges","volume":"24","author":"F Westermeier","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"pone.0354497.ref003","doi-asserted-by":"crossref","first-page":"721135","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects","volume":"12","author":"X Zhao","year":"2021","journal-title":"Front Endocrinol"},{"key":"pone.0354497.ref004","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.biopha.2018.08.088","article-title":"Recent updates on GLP-1 agonists: current advancements & challenges","volume":"108","author":"D Sharma","year":"2018","journal-title":"BioMed Pharmacother"},{"issue":"2","key":"pone.0354497.ref005","first-page":"101","article-title":"Pharmacokinetics and pharmacodynamics of GLP-1 receptor agonists","volume":"33","author":"MA Nauck","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"4","key":"pone.0354497.ref006","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1","volume":"27","author":"DJ Drucker","year":"2018","journal-title":"Cell Metab"},{"issue":"1","key":"pone.0354497.ref007","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ajg.2012.373","article-title":"Clinical guideline: management of gastroparesis","volume":"108","author":"American College of Gastroenterology","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"pone.0354497.ref008","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1053\/j.gastro.2004.09.055","article-title":"American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis","volume":"127","author":"American Gastroenterological Association","year":"2004","journal-title":"Gastroenterology"},{"issue":"1","key":"pone.0354497.ref009","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s12020-025-04494-3","article-title":"Exploring the rates of Gastrointestinal adverse effects among five GLP-1 receptor agonists: A systematic review and Meta-Analysis of randomized controlled trials","volume":"91","author":"B Joy","year":"2026","journal-title":"Endocrine"},{"key":"pone.0354497.ref010","doi-asserted-by":"crossref","first-page":"1149328","DOI":"10.3389\/fendo.2023.1149328","article-title":"GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis","volume":"14","author":"Z Zhang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"pone.0354497.ref011","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1053\/j.gastro.2025.06.003","article-title":"Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis","volume":"169","author":"C-H Chiang","year":"2025","journal-title":"Gastroenterology"},{"issue":"4","key":"pone.0354497.ref012","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.gie.2024.12.019","article-title":"Glucagon-like peptide-1 receptor agonist use and the risk of residual gastric contents and aspiration in patients undergoing GI endoscopy: a systematic review and a meta-analysis","volume":"101","author":"MU Baig","year":"2025","journal-title":"Gastrointest Endosc"},{"issue":"8","key":"pone.0354497.ref013","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.1007\/s00464-025-11962-4","article-title":"Impact of GLP-1 receptor agonists on upper gastrointestinal endoscopy: an updated systematic review and meta-analysis","volume":"39","author":"A Abdulraheem","year":"2025","journal-title":"Surg Endosc"},{"key":"pone.0354497.ref014","doi-asserted-by":"crossref","DOI":"10.2174\/0118743064372550250603061720","article-title":"GLP-1 Agonists and the Risk of Pulmonary Aspiration during Elective Upper Endoscopy: A Systematic Review and Meta-analysis","volume":"19","author":"PR Elmati","year":"2025","journal-title":"Open Respir Med J"},{"key":"pone.0354497.ref015","author":"JBI Global"},{"issue":"12","key":"pone.0354497.ref016","article-title":"Liraglutide-induced acute gastroparesis","volume":"10","author":"P Rai","year":"2018","journal-title":"Cureus"},{"issue":"9","key":"pone.0354497.ref017","article-title":"Unmasking semaglutide-induced gastroparesis: the dangers of rapid dose escalation in a diabetic patient","volume":"17","author":"R Singhal","year":"2025","journal-title":"Cureus"},{"issue":"11","key":"pone.0354497.ref018","article-title":"Gastroparesis With the Initiation of Liraglutide: A Case Report","volume":"12","author":"S Almustanyir","year":"2020","journal-title":"Cureus"},{"issue":"7","key":"pone.0354497.ref019","article-title":"Suspected gastroparesis with concurrent gastroesophageal reflux disease induced by low-dose liraglutide","volume":"14","author":"Y Ishihara","year":"2022","journal-title":"Cureus"},{"issue":"1","key":"pone.0354497.ref020","article-title":"Tendency of semaglutide to induce gastroparesis: A case report","volume":"16","author":"A Chaudhry","year":"2024","journal-title":"Cureus"},{"key":"pone.0354497.ref021","article-title":"Medication-Induced Gastroparesis: A Case Report","volume":"9","author":"MA Kalas","year":"2021","journal-title":"J Investig Med High Impact Case Rep"},{"key":"pone.0354497.ref022","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvae163.780","article-title":"6486 Gastroparesis Exacerbation by a GLP-1 Agonist","volume":"8","author":"JM Deirmenjian","year":"2024","journal-title":"Journal of the Endocrine Society"},{"key":"pone.0354497.ref023","article-title":"Slow down and think about it: differentiating causes of gastroparesis in patients with diabetes","volume":"38","author":"N Chahal","year":"2023","journal-title":"Injournal of General Internal Medicine"},{"issue":"2","key":"pone.0354497.ref024","first-page":"527","article-title":"Is gastroparesis always irreversible in a diabetic?: 275","volume":"69","author":"M Kalas","year":"2021","journal-title":"Journal of Investigative Medicine"},{"key":"pone.0354497.ref025","article-title":"Speed up a slow down: Recognizing GLP-1 gastroparesis and SGLT-2 euglycemic DKA","volume-title":"Journal of General Internal Medicine","author":"C McGee","year":"2020"},{"issue":"1","key":"pone.0354497.ref026","doi-asserted-by":"crossref","first-page":"71","DOI":"10.47892\/rgp.2024.441.1527","article-title":"Severe gastroparesia associated with the use of GLP-1 receptor agonists for weight loss","volume":"44","author":"SA Ch\u00e1vez-S\u00e1nchez","year":"2024","journal-title":"Rev Gastroenterol Peru"},{"key":"pone.0354497.ref027","doi-asserted-by":"crossref","DOI":"10.14309\/01.ajg.0000966968.44182.37","article-title":"S4332\u2003I Miss Eating: Medication-Induced Gastroparesis from Semaglutide","volume":"118","author":"P Gomez","year":"2023","journal-title":"Am J Gastroenterol"},{"issue":"23","key":"pone.0354497.ref028","doi-asserted-by":"crossref","first-page":"104932","DOI":"10.3748\/wjg.v31.i23.104932","article-title":"Gastroparesis, a diabetic complication causing further, even serious, complications: How to prevent its worsening?","volume":"31","author":"M Bortolotti","year":"2025","journal-title":"World J Gastroenterol"},{"issue":"8","key":"pone.0354497.ref029","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/oby.23481","article-title":"Effects of liraglutide on gastrointestinal functions and weight in obesity: A randomized clinical and pharmacogenomic trial","volume":"30","author":"D Maselli","year":"2022","journal-title":"Obesity (Silver Spring)"},{"issue":"4","key":"pone.0354497.ref030","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/dom.12596","article-title":"Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists","volume":"18","author":"S Madsbad","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"pone.0354497.ref031","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.2337\/dc20-0720","article-title":"Effects of lixisenatide versus liraglutide (short- and long-acting GLP-1 receptor agonists) on esophageal and gastric function in patients with type 2 diabetes","volume":"43","author":"DR Quast","year":"2020","journal-title":"Diabetes Care"},{"issue":"43","key":"pone.0354497.ref032","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000035739","article-title":"Effect of long-acting versus short-acting glucagon-like peptide-1 receptor agonists on improving body weight and related metabolic parameters in type 2 diabetes: A head-to-head meta-analysis","volume":"102","author":"X Yuan","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"pone.0354497.ref033","article-title":"Compare and contrast the glucagon-like peptide-1 receptor agonists (GLP1RAs)","volume-title":"StatPearls","author":"W Latif","year":"2025"},{"issue":"1","key":"pone.0354497.ref034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gtc.2014.11.001","article-title":"Gastroparesis: definitions and diagnosis","volume":"44","author":"PJ Pasricha","year":"2015","journal-title":"Gastroenterol Clin North Am"},{"issue":"12","key":"pone.0354497.ref035","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1136\/gut.2009.199703","article-title":"Diabetic gastroparesis: what we have learned and had to unlearn in the past 5 years","volume":"59","author":"P Kashyap","year":"2010","journal-title":"Gut"},{"issue":"1","key":"pone.0354497.ref036","article-title":"Functional dyspepsia and gastroparesis: are they distinct disorders, a spectrum of diseases or one disease?","volume":"3","author":"S-M Egboh","year":"2025","journal-title":"eGastroenterology"},{"issue":"1","key":"pone.0354497.ref037","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2024-001463","article-title":"Digital disease management programme reduces chronic gastrointestinal symptoms among racially and socially vulnerable populations","volume":"11","author":"D Bravata","year":"2024","journal-title":"BMJ Open Gastroenterol"},{"issue":"4","key":"pone.0354497.ref038","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/gutjnl-2025-336908","article-title":"Differentiating gastroparesis from functional dyspepsia is no longer sufficient","volume":"75","author":"G O\u2019Grady","year":"2026","journal-title":"Gut"},{"issue":"1","key":"pone.0354497.ref039","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2024-001704","article-title":"Comparing the risk of gastroparesis following different modalities for treating obesity: semaglutide versus bupropion-naltrexone versus sleeve gastrectomy - a retrospective cohort study","volume":"12","author":"C Aneke-Nash","year":"2025","journal-title":"BMJ Open Gastroenterol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0354497","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T17:25:31Z","timestamp":1786641931000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0354497"}},"subtitle":[],"editor":[{"given":"Lanlan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":39,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0354497","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]}}}